C
Craig B. Reeder
Researcher at Mayo Clinic
Publications - 197
Citations - 10346
Craig B. Reeder is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Lenalidomide & Multiple myeloma. The author has an hindex of 45, co-authored 185 publications receiving 9395 citations. Previous affiliations of Craig B. Reeder include University of Nebraska Omaha & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Alan F. List,Gordon W. Dewald,John M. Bennett,A. Giagounidis,Azra Raza,Eric J. Feldman,Bayard L. Powell,Peter L. Greenberg,Deborah A. Thomas,Richard Stone,Craig B. Reeder,Kenton Wride,John Patin,Michele Schmidt,Jerome B. Zeldis,Robert Knight +15 more
TL;DR: Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.
Journal ArticleDOI
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard Piekarz,Robin Frye,Maria L. Turner,John Wright,Steven L. Allen,Mark Kirschbaum,Jasmine Zain,H. Miles Prince,John P. Leonard,Larisa J. Geskin,Craig B. Reeder,David Joske,William D. Figg,Erin R. Gardner,Seth M. Steinberg,Elaine S. Jaffe,Maryalice Stetler-Stevenson,Stephen Lade,A. Tito Fojo,Susan E. Bates +19 more
TL;DR: The histone deacetylase inhibitor romidepsin has single-agent clinical activity with significant and durable responses in patients with CTCL.
Journal ArticleDOI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar,Joseph R. Mikhael,Francis K. Buadi,David Dingli,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Philip R. Greipp,Suzanne R. Hayman,Robert A. Kyle,Martha Q. Lacy,John A. Lust,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Kristen Detweiler Short,A. Keith Stewart,Thomas E. Witzig,Steven R. Zeldenrust,Robert J. Dalton,S. Vincent Rajkumar,P. Leif Bergsagel +21 more
TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Journal ArticleDOI
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma
Thomas E. Witzig,Julie M. Vose,Pier Luigi Zinzani,Craig B. Reeder,Rena Buckstein,Jonathan Polikoff,R. Bouabdallah,Corinne Haioun,H. Tilly,Pingshan Guo,Dennis Pietronigro,Annette Ervin-Haynes,Myron S. Czuczman +12 more
TL;DR: Lenalidomide is well tolerated and produces durable responses in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Journal ArticleDOI
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Craig B. Reeder,Donna E. Reece,Vishal Kukreti,Christine Chen,Suzanne Trudel,Joseph G. Hentz,Brie N. Noble,Nicholas A. Pirooz,Jacy Spong,Jesus Giovanni Piza,V H J Zepeda,Joseph R. Mikhael,Jose F. Leis,P L Bergsagel,R Fonseca,Alexander Keith Stewart +15 more
TL;DR: In conclusion, CyBorD produces a rapid and profound response in patients with newly diagnosed multiple myeloma with manageable toxicity.